Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Leading MS pharmaceutical drugs in the U.S. by revenue 2013

This statistic displays the top 10 multiple sclerosis FDA-approved drugs based on revenues globally in 2013. During this year, Tecfidera (dimethyl fumurate), sponsored and developed by Biogen Idec, generated 876 million U.S. dollars in revenue. Tecfidera is used primarily for relapsing forms of MS. MS is a disease that damages nerve cells in the brain and spinal cord which disrupts the ability of the nervous system to communicate with the body.

Top 10 multiple sclerosis drugs worldwide by revenue in 2013

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

February 2014

Region

Worldwide, United States

Survey time period

2013

Supplementary notes

Statistic includes only FDA-approved drugs.
* Mostly U.S. sales.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.